Biodegradable Polymeric Valve Scaffold for Cardiac Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac valves, whether mechanical, bioprosthetic, or tissue-engineered, face issues such as thrombogenicity, durability concerns, and the need for anticoagulant therapy, with tissue-engineered valves being non-regenerative and requiring frequent replacements, especially in children, and existing fabrication methods being complex and prone to failure at high-stress points.
Innovation Solution
The development of engineered tubular structures comprising oriented polymeric fibers, specifically nanofibers, which form a suture-free valve with integral leaflets, eliminating the need for sutures and melt processing, and allowing for cellular ingrowth, thereby enhancing durability and reducing stress points.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If mechanical valves are used, then durability and robustness are improved, but thrombogenicity increases requiring lifetime anticoagulant therapy
Solution Approach 1:
The patent employs a biodegradable polymeric scaffold that gradually degrades over time, transitioning from a mechanical support structure to allowing natural tissue formation. This replaces the permanent mechanical valve with a temporary scaffold that is ultimately replaced by living tissue, eliminating long-term thrombogenicity while providing initial mechanical durability.
Solution Approach 2:
The patent changes the material parameters from permanent synthetic materials to biodegradable polymers with controlled degradation rates. The scaffold's mechanical properties evolve over time as it degrades, initially providing structural support then gradually transferring load to regenerating native tissue, resolving the contradiction between initial durability and long-term biocompatibility.
2Object-affected harmful factors
If bioprosthetic valves are used, then thrombogenicity is reduced, but durability decreases due to tissue calcification and stiffening
Solution Approach 1:
The patent enables the valve to self-repair and self-regenerate by providing a scaffold that promotes native tissue cell migration and proliferation. The structure serves itself by facilitating the growth of healthy, non-calcifying tissue that replaces the scaffold over time, eliminating the need for external intervention and preventing the calcification that plagues bioprosthetic valves.
Solution Approach 2:
The patent uses composite construction combining biodegradable polymeric scaffold materials with biological components that promote tissue regeneration. This composite approach creates a temporary synthetic structure that actively facilitates the formation of permanent biological tissue, combining the initial mechanical reliability of synthetics with the long-term biocompatibility of native tissue.
3Object-affected harmful factors
If tissue-engineered valves with degradable scaffolds are used, then thrombogenicity is reduced and tissue regeneration is promoted, but manufacturing complexity and cost increase
Solution Approach 1:
The patent divides the valve structure into distinct functional segments: a tubular wall portion and integrated leaflet portions, both formed from the same biodegradable scaffold material. This segmentation allows for modular design and simplified manufacturing while maintaining the complexity needed for tissue regeneration functionality.
Solution Approach 2:
The patent merges the tubular wall and leaflet structures into a single integrated scaffold component, eliminating the need for separate fabrication and assembly of these parts. This consolidation reduces manufacturing steps and complexity while maintaining the sophisticated three-dimensional architecture required for promoting tissue regeneration and achieving thromboresistance.
4Object-affected harmful factors
If current tissue-engineered valves are used, then anticoagulant therapy is not needed, but durability decreases due to fatigue from mechanical cycling
Solution Approach 1:
The patent implements preliminary action by providing a mechanically robust scaffold structure that immediately withstands physiological cycling stresses before native tissue has fully regenerated. The scaffold is pre-engineered to bear the full mechanical load during the critical early period, preventing fatigue failure before the permanent biological tissue is established.
Solution Approach 2:
The patent provides beforehand cushioning through the biodegradable scaffold that protects the developing native tissue from excessive mechanical stresses during the regeneration process. The scaffold gradually transfers load as tissue strengthens, providing protective support during the vulnerable transition period and preventing premature fatigue failure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a durable, biocompatible cardiac valve that mimics human cardiac function, reduces the risk of valve failure, and promotes tissue integration, potentially eliminating the need for anticoagulant therapy and minimizing surgical complexity.
Implementation Method 1
micron, submicron or nanometer dimension polymer fibers defining a shape of the tubular wall... configured to form a polymeric fiber scaffold for cellular ingrowth
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2B
AI summary
The present invention provides engineered valves, tubular structures, and sheets comprising oriented polymeric fibers, e.g., nanofibers, methods of fabricating such structures, and methods of use of such structures as, for example, patches, grafts and valves, e.g., cardiac valves.